The SEC asks Novartis, ‘Haven't we met before?’
After settling an FCPA enforcement brought by the SEC in March, Novartis is now under criminal investigation in South Korea for alleged illegal payments to physcians. Should the SEC reopen its investigation?
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleSEC closes FCPA probe into Calavo Growers
The Securities and Exchange Commission has closed its Foreign Corrupt Practices Act investigation into Calavo Growers, three months after the Department of Justice closed its FCPA investigation into the produce and agriculture company.
-
ArticleSEC drops all charges against former Rio Tinto CFO related to coal valuation
The U.S. Securities and Exchange Commission dropped its case against Rio Tinto’s former chief financial officer, who has battled charges for eight years.
-
ArticleTop Ethics and Compliance Failures of 2025
The 2025 year has been so rich with compliance stinkers, and rife with poor judgment, compliance missteps, outright malfeasance and greed, greed, greed, that it was almost impossible to choose just six epic compliance failures from this year’s massive poop pile.